Anika Therapeutics Analyst Ratings
Anika Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 30.58% | Barrington Research | → $24 | Upgrades | Market Perform → Outperform |
| 08/10/2023 | 25.14% | Stephens & Co. | $28 → $23 | Maintains | Equal-Weight |
| 05/31/2023 | 52.34% | Stephens & Co. | → $28 | Reiterates | Equal-Weight → Equal-Weight |
| 04/14/2023 | 52.34% | Stephens & Co. | → $28 | Reiterates | → Equal-Weight |
| 03/07/2023 | — | Barrington Research | Downgrades | Outperform → Market Perform | |
| 11/09/2022 | 68.66% | Barrington Research | → $31 | Upgrades | Market Perform → Outperform |
| 10/14/2022 | 41.46% | Stephens & Co. | → $26 | Reinstates | → Equal-Weight |
| 03/09/2022 | — | Stephens & Co. | Downgrades | Overweight → Equal-Weight | |
| 11/16/2021 | 199.24% | Stephens & Co. | → $55 | Initiates Coverage On | → Overweight |
| 07/16/2021 | 150.27% | UBS | → $46 | Initiates Coverage On | → Neutral |
| 12/16/2020 | 133.95% | Barrington Research | → $43 | Upgrades | Market Perform → Outperform |
| 01/21/2020 | 231.88% | Sidoti & Co. | → $61 | Upgrades | Neutral → Buy |
| 11/05/2019 | 57.78% | BWS Financial | → $29 | Initiates Coverage On | → Sell |
| 09/23/2019 | — | First Analysis | Downgrades | Strong Buy → Outperform | |
| 02/22/2019 | 123.07% | Sidoti & Co. | $56 → $41 | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月14日 | 30.58% | 巴靈頓研究公司 | →$24 | 升級 | 市場表現優於→ |
| 2023年08月10日 | 25.14% | 斯蒂芬斯公司 | $28→$23 | 維護 | 等重 |
| 2023年05月31日 | 52.34% | 斯蒂芬斯公司 | →$28 | 重申 | 等重→等重 |
| 04/14/2023 | 52.34% | 斯蒂芬斯公司 | →$28 | 重申 | →等重 |
| 03/07/2023 | - | 巴靈頓研究公司 | 評級下調 | 跑贏→市場表現 | |
| 11/09/2022 | 68.66% | 巴靈頓研究公司 | →$31 | 升級 | 市場表現優於→ |
| 10/14/2022 | 41.46% | 斯蒂芬斯公司 | →$26 | 恢復 | →等重 |
| 03/09/2022 | - | 斯蒂芬斯公司 | 評級下調 | 超重→等重 | |
| 2021年11月16日 | 199.24% | 斯蒂芬斯公司 | →$55 | 開始承保 | →超重 |
| 07/16/2021 | 150.27% | 瑞銀集團 | →$46 | 開始承保 | →中性 |
| 12/16/2020 | 133.95% | 巴靈頓研究公司 | →$43 | 升級 | 市場表現優於→ |
| 2020/01/21 | 231.88% | 西多蒂公司 | →$61 | 升級 | 中性→購買 |
| 2019年11月05日 | 57.78% | BWS金融 | →$29 | 開始承保 | →銷售 |
| 2019年09月23日 | - | 第一次分析 | 評級下調 | 強勢買入→跑贏大盤 | |
| 2019年02月22日 | 123.07% | 西多蒂公司 | $56→$41 | 評級下調 | 購買→中性 |
What is the target price for Anika Therapeutics (ANIK)?
Anika Treeutics(Anik)的目標價格是多少？
The latest price target for Anika Therapeutics (NASDAQ: ANIK) was reported by Barrington Research on August 14, 2023. The analyst firm set a price target for $24.00 expecting ANIK to rise to within 12 months (a possible 30.58% upside). 7 analyst firms have reported ratings in the last year.
巴靈頓研究公司於2023年8月14日報道了Anika治療公司(納斯達克：ANIK)的最新目標價。這家分析公司將目標價定為24美元，預計Anik將在12個月內上漲(可能上漲30.58%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Anika Therapeutics (ANIK)?
Anika Treeutics(Anik)的最新分析師評級是什麼？
The latest analyst rating for Anika Therapeutics (NASDAQ: ANIK) was provided by Barrington Research, and Anika Therapeutics upgraded their outperform rating.
巴靈頓研究公司提供了對Anika治療公司(納斯達克代碼：ANIK)的最新分析師評級，Anika治療公司上調了其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Anika Therapeutics (ANIK)?
Anika Treeutics(Anik)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公共財務報表，與Anika Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Anika治療公司的上一次評級是在2023年8月14日提交的，所以你應該預計下一次評級將在2024年8月14日左右的某個時候提供。
Is the Analyst Rating Anika Therapeutics (ANIK) correct?
分析師對Anika Treeutics(Anik)的評級正確嗎？
While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a upgraded with a price target of $0.00 to $24.00. The current price Anika Therapeutics (ANIK) is trading at is $18.38, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Anika Treeutics(Anik)評級被上調，目標價從0.00美元到24.00美元。Anika Treateutics(Anik)目前的交易價格為18.38美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。